Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

The landscape of transcriptomic and proteomic studies in sarcoidosis

Maneesh Bhargava, Shu-Yi Liao, Elliott D. Crouser, Lisa A. Maier, Sonia M. Leach
ERJ Open Research 2022 8: 00621-2021; DOI: 10.1183/23120541.00621-2021
Maneesh Bhargava
1Division of Pulmonary, Critical Care and Sleep Medicine, Dept of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
7These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bharg005@umn.edu
Shu-Yi Liao
2Division of Environmental and Occupational Health Sciences, Dept of Medicine, National Jewish Health, Denver, CO, USA
3Division of Pulmonary Sciences and Critical Care Medicine, Dept of Medicine, University of Colorado Denver, Aurora, CO, USA
4Dept of Environmental and Occupational Health, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA
7These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elliott D. Crouser
5Division of Pulmonary and Critical Care Medicine, The Ohio State University, Columbus, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa A. Maier
2Division of Environmental and Occupational Health Sciences, Dept of Medicine, National Jewish Health, Denver, CO, USA
3Division of Pulmonary Sciences and Critical Care Medicine, Dept of Medicine, University of Colorado Denver, Aurora, CO, USA
4Dept of Environmental and Occupational Health, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonia M. Leach
6Center for Genes, Environment and Health, National Jewish Health, Denver, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Multiple overlapping pathways are identified in tissue, BAL cells, PBMCs and a sarcoidosis in vitro granuloma model. Inferences from omic studies are constrained by small sample sizes. Studies comparing differences between sarcoidosis phenotypes are needed. https://bit.ly/30NaHz4

To the Editor:

Sarcoidosis is a systemic disease with gene/protein expression patterns that may be different among different tissues, based on the presence or absence of granulomas, and on subphenotypes with progressive or nonprogressive disease manifestations. There is a growing body of data evaluating global transcriptomic changes across multiple tissue compartments in sarcoidosis. However, whether similar biological pathways are involved is unknown. Furthermore, an understanding of the transcriptional impact on the proteome is required to validate molecular pathways driving heterogeneity in sarcoidosis. The purpose of this study was to compare biological inferences from published datasets and explore the compartment specificity of these responses in sarcoidosis. Common pathways identified across datasets or tissue types may serve as convenient biomarkers and could lead to the discovery of novel therapeutic targets.

We identified published sarcoidosis studies of differentially expressed genes (DEGs) (via microarray, bulk or single-cell RNA sequencing) or differentially abundant proteins (DAPs) (via unbiased proteome-wide screens) through PubMed and Gene Expression Omnibus (GEO). These studies compared cases with controls or compared progressive versus nonprogressive pulmonary sarcoidosis phenotypes in peripheral blood or peripheral blood mononuclear cells (PBMCs), bronchoalveolar lavage (BAL) cells or fluid, lung tissue, microdissected lung granulomas, lymph nodes, or an established in vitro granuloma model (stimulated PBMCs). The definition of progressive versus nonprogressive pulmonary sarcoidosis varied among studies but overall, progressive sarcoidosis referred to worsening chest imaging, need for systemic anti-inflammatory therapy and/or worsening lung function or symptoms. When DEG/DAP lists were not already available as supplementary information in the publication or did not originate from our laboratories, we downloaded the expression data as processed by the original authors from GEO and used the R package DEseq2 for RNA sequencing data or limma for microarray data to compute a DEG list, controlling for Benjamini and Hochberg's false discovery rate (FDR) <0.1 and compared to results found when using uncorrected p-value <0.05. Significantly enriched pathways found for each DEG/DAP independently using Ingenuity Pathway Analysis (QIAGEN Inc.) at FDR <0.05 were summarised in a visualisation across studies using the R pheatmap package.

Using 15 datasets [1–11] with 10 datasets comparing sarcoidosis to control and five comparing sarcoidosis phenotypes (progressive versus nonprogressive) (figure 1f), de novo pathway analyses revealed 549 canonical pathways mapping to DEGs or DAPs. Of these, 181 pathways were present in more than four of 15 datasets, several of which have previously been investigated (more than three PubMed publications) (figure 1a) but some not well studied thus far (three or fewer PubMed publications) (figure 1b), such as integrin signalling, interleukin (IL)-8 signalling and neuroinflammation signalling. All but one of the 181 overlapping pathways were present in sarcoidosis lungs or lymph nodes compared to controls (figure 1e). 164 (91%) of these pathways were also identified in peripheral blood (figure 1c). In contrast, 16 (9%) canonical pathways were only detected in lungs or lymph nodes or BAL but not in peripheral blood (figure 1d), including mechanistic target of rapamycin signalling, phagosome formation, phagosome maturation, Janus kinase–signal tranducer and activator of transcription or Rho–Rac kinase signalling. Among the 181 pathways distinguishing sarcoidosis from controls, 161 (89%) were also detected in the progressive versus nonprogressive comparison. There were no pathways specific to the progressive versus nonprogressive comparison that were not present in the sarcoidosis versus control comparison. The pathways enriched in the in vitro granuloma model were all represented in lungs, lymph nodes or BAL, and 97% were represented in peripheral blood.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Summary of existing transcriptional and proteomic studies in sarcoidosis: 10 datasets comparing sarcoidosis (Sarc) with healthy controls (Ctrl) and five comparing progressive (P) to nonprogressive (NP) sarcoidosis were analysed. Differentially expressed genes (DEGs) and differentially abundant proteins (DAPs) were used for “core analysis” with Ingenuity Pathway Analysis (IPA) to identify over-represented canonical pathways for each dataset controlling for a false-discovery rate (FDR) at <0.05. IPA “comparison analysis” tool was used to determine the common canonical pathways across various datasets studied. We focused on pathways observed in at least five datasets, showing the top 50 overall and 16 not found in blood. a) The canonical pathways that were well established based on prior studies (more than three PubMed publications); b) pathways that have limited studies published to date in sarcoidosis (three or fewer PubMed publications); c) some of the pathways common to lung/lymph node tissue, bronchoalveolar lavage (BAL) and blood or peripheral blood mononuclear cells (PBMCs) and the in vitro granuloma model; d) pathways only detected in the BAL/lung/lymph node but not in peripheral blood cells and to a lesser degree in the in vitro granuloma model; e) the numbers of overlapping pathways among different tissues presented as a Venn diagram; and f) an overview of the referenced datasets. #: P (active) versus NP (non-active); ¶: untreated P (chronic Stage II/III) versus NP (non-acute or remitting Stage 0/I); Th: helper T-cell; FcγR: IgG receptor; ERK: extracellular signal-regulated kinase; MAPK: mitogen-activated protein kinase; PI3K: phosphoinositide 3-kinase; GDI: GDP dissociation inhibitor; mTOR: mechanistic target of rapamycin; PD-L1: PD-1 ligand; IL: interleukin; HIF: hypoxia-inducible factor; HER: human epidermal growth factor receptor; FAK: focal adhesion kinase; fMLP: N-formyl-methionyl-leucyl-phenylalanine; LXR: liver X receptor; RXR: retinoid X receptor; PTEN: phosphatase and tensin homologue; AHR: aryl hydrocarbon receptor; FXR: farnesoid X receptor; BALC: bronchoalveolar lavage cells; BALF: bronchoalveolar lavage fluid; sc: single-cell; RNA-seq: RNA sequencing; LC MS/MS: liquid chromatography–tandem mass spectrometry; PMID: PubMed identifier.

Our integrative analysis identified many canonical pathways apparent in multiple tissue compartments and those unique to a specific compartment. Most studies compared sarcoidosis to controls, whereas mechanisms of progression are best studied when comparing sarcoidosis phenotypes. Many pathways observed in our analysis were well established in sarcoidosis pathogenesis, such as antigen presentation, helper T-cell (Th)1 and Th2 activation, etc., as noted above and in figure 1. Some of the canonical pathways were identified only in BAL, lungs or lymph nodes, reflecting compartment-specific granulomatous inflammatory mechanisms. Other pathways were present in blood and BAL, lungs or lymph nodes, reflecting systemic immune alterations. The well-established in vitro granuloma model demonstrates substantial overlap with diseased lung and lymph node tissues, reflective of in vivo granulomatous inflammation. For the protein dataset, the DAP map included fewer canonical pathways, likely due to a smaller number of proteins identified by contemporary technologies. However, altered protein pathways could be high-priority targets for testing as therapeutic targets or for further characterisation by classical molecular techniques.

Our analyses revealed new and novel pathways in sarcoidosis, highlighting the power of “unbiased discovery.” For example, neuroinflammatory response has not been previously well studied in sarcoidosis. However, neuroinflammation signalling was identified in all compartments and might implicate neurotoxic cytokines or ILs [12]. Likewise, the prolactin signalling pathway, which regulates pro- and anti-inflammatory cytokines in the context of neural damage [13], was detected in all tissues. It is interesting to speculate that neuroinflammatory pathways might contribute to neurocognitive manifestations commonly observed in pulmonary sarcoidosis. Other pathways identified, such as integrin signalling, might participate in granuloma formation, promoting cell adhesion, and regulating immune cell survival, polarity, proliferation in pulmonary sarcoidosis [14]. Our novel discovery of enhanced caveolae-mediated endocytic signalling elements implies altered environmental antigen processing that could promote granulomatous inflammation. Similarly, aryl hydrocarbon receptor (AHR) signalling is emerging as an important immunoregulator in response to endogenous and exogenous ligands; AHR regulates T-cell responses at multiple levels, including T-cell fate, induction of CD4+ regulatory T-cells and Th17s, and Th22 cell differentiation, balancing effector and regulatory cells [15]. AHR signalling is implicated in other granulomatous diseases such as Crohn's disease. Enhanced antigen processing (e.g. caveolae-mediated and phagolysosomal) and related T-cell responses were expected, and likely drive a strong adaptive immune response; our analysis also provides evidence for aberrant innate immune responses that likely contribute to sarcoidosis development and progression. The IL-8 signalling pathway, promoting granulocytic inflammation and phagocytosis, is increased in sarcoidosis versus controls and distinguished progressive from nonprogressive based on DEGs and DAPs. Supporting this finding, higher IL-8 levels are reported in chronic sarcoidosis.

Our analysis was restricted to datasets that were publicly available in a format allowing identification of differentially expressed features and thus may have excluded some important studies not available in this format. In addition, as we only had summary statistics available instead of individual data with detailed information, we cannot account for differences in race and ethnicity. While the definition for sarcoidosis was uniform among studies, pulmonary phenotypes and the definition of progressive versus nonprogressive varied among studies; this may have limited our detection of phenotypic pathways. We summarised enriched pathways across studies rather than comparing DEG and DAP lists directly or attempting to analyse the studies as a single dataset to minimise biases due to variable sample numbers, the number of features assayed by each platform or other sources of variance across studies. Although differences in sample size implicitly bias the size of the resulting DEG/DAP list, the pathway enrichment statistic accounts for input list size. However, emphasis should be placed on detection of an enriched pathway across multiple studies, rather than the lack of detection, since no detection in a given study could be attributed to lack of power, not lack of biological relevance. Our analysis highlights the paucity of comprehensive studies integrating omics and systems biology in sarcoidosis. Pathways involved in granulomatous inflammation can be identified in lungs, lymph nodes, BAL cells or fluid, and/or blood. Evaluation of each compartment may answer specific questions; blood or BAL may be useful to develop biomarkers, while lung and lymph nodes may be superior for investigating disease biology. We have demonstrated that findings from one compartment, such as blood, can be seen in respiratory tract specimens to define pathways shared and distinct across compartments. The in vitro granuloma model demonstrates pathways that overlap with both lung and blood, providing a highly relevant and convenient tool to improve knowledge in sarcoidosis. As most studies examined sarcoidosis versus controls and did not consider pulmonary phenotypes, the latter is an urgent unmet research need as pulmonary sarcoidosis results in significant sarcoidosis-related mortality; carefully designed studies designed to narrow existing knowledge gaps in mechanisms driving sarcoidosis heterogeneity are needed.

Footnotes

  • Provenance: Submitted article, peer reviewed.

  • Conflict of interest: M. Bhargava has nothing to disclose.

  • Conflict of interest: S-Y. Liao has nothing to disclose.

  • Conflict of interest: E.D. Crouser has nothing to disclose.

  • Conflict of interest: L.A. Maier has nothing to disclose.

  • Conflict of interest: S.M. Leach has nothing to disclose.

  • Support statement: This study was supported by a Foundation for Sarcoidosis Research grant to E.D. Crouser and S-Y. Liao; and National Institutes of Health grants HL077466 to E.D. Crouser, HL112695 and HL112707 to L.A. Maier, HL140357 to L.A. Maier and S-Y. Liao, and HL153613 to M. Bhargava and L.A. Maier. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received November 3, 2021.
  • Accepted November 16, 2021.
  • Copyright ©The authors 2022
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Bhargava M,
    2. Viken KJ,
    3. Barkes B, et al.
    Novel protein pathways in development and progression of pulmonary sarcoidosis. Sci Rep 2020; 10: 13282. doi:10.1038/s41598-020-69281-8
    OpenUrl
    1. Casanova NG,
    2. Gonzalez-Garay ML,
    3. Sun B, et al.
    Differential transcriptomics in sarcoidosis lung and lymph node granulomas with comparisons to pathogen-specific granulomas. Respir Res 2020; 21: 321. doi:10.1186/s12931-020-01537-3
    OpenUrl
    1. Crouser ED,
    2. Culver DA,
    3. Knox KS, et al.
    Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med 2009; 179: 929–938. doi:10.1164/rccm.200803-490OC
    OpenUrlCrossRefPubMed
    1. Garman L,
    2. Pelikan RC,
    3. Rasmussen A, et al.
    Single cell transcriptomics implicate novel monocyte and T cell immune dysregulation in sarcoidosis. Front Immunol 2020; 11: 567342. doi:10.3389/fimmu.2020.567342
    OpenUrl
    1. Koth LL,
    2. Solberg OD,
    3. Peng JC, et al.
    Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med 2011; 184: 1153–1163. doi:10.1164/rccm.201106-1143OC
    OpenUrlCrossRefPubMed
    1. Liao SY,
    2. Atif SM,
    3. Mould K, et al.
    Single-cell RNA sequencing identifies macrophage transcriptional heterogeneities in granulomatous diseases. Eur Respir J 2021; 57: 2003794. doi:10.1183/13993003.03794-2020
    OpenUrlAbstract/FREE Full Text
    1. Locke LW,
    2. Crouser ED,
    3. White P, et al.
    IL-13-regulated macrophage polarization during granuloma formation in an in vitro human sarcoidosis model. Am J Respir Cell Mol Biol 2019; 60: 84–95. doi:10.1165/rcmb.2018-0053OC
    OpenUrlCrossRef
    1. Lockstone HE,
    2. Sanderson S,
    3. Kulakova N, et al.
    Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis. Am J Respir Crit Care Med 2010; 181: 1367–1375. doi:10.1164/rccm.200912-1855OC
    OpenUrlCrossRefPubMed
    1. Rosenbaum JT,
    2. Pasadhika S,
    3. Crouser ED, et al.
    Hypothesis: sarcoidosis is a STAT1-mediated disease. Clin Immunol 2009; 132: 174–183. doi:10.1016/j.clim.2009.04.010
    OpenUrlCrossRefPubMed
    1. Vukmirovic M,
    2. Yan X,
    3. Gibson KF, et al.
    Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis. Eur Respir J 2021; 58: 2002950. doi:10.1183/13993003.02950-2020
    OpenUrl
  2. ↵
    1. Zhou T,
    2. Zhang W,
    3. Sweiss NJ, et al.
    Peripheral blood gene expression as a novel genomic biomarker in complicated sarcoidosis. PLoS One 2012; 7: e44818. doi:10.1371/journal.pone.0044818
    OpenUrlCrossRefPubMed
  3. ↵
    1. Becher B,
    2. Spath S,
    3. Goverman J
    . Cytokine networks in neuroinflammation. Nat Rev Immunol 2017; 17: 49–59. doi:10.1038/nri.2016.123
    OpenUrlCrossRef
  4. ↵
    1. Ramos-Martinez E,
    2. Ramos-Martinez I,
    3. Molina-Salinas G, et al.
    The role of prolactin in central nervous system inflammation. Rev Neurosci 2021; 32: 323–340. doi:10.1515/revneuro-2020-0082
    OpenUrl
  5. ↵
    1. Teoh CM,
    2. Tan SS,
    3. Tran T
    . Integrins as therapeutic targets for respiratory diseases. Curr Mol Med 2015; 15: 714–734. doi:10.2174/1566524015666150921105339
    OpenUrlCrossRef
  6. ↵
    1. Gutierrez-Vazquez C,
    2. Quintana FJ
    . Regulation of the immune response by the Aryl hydrocarbon receptor. Immunity 2018; 48: 19–33. doi:10.1016/j.immuni.2017.12.012
    OpenUrl
PreviousNext
Back to top
Vol 8 Issue 1 Table of Contents
ERJ Open Research: 8 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The landscape of transcriptomic and proteomic studies in sarcoidosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
The landscape of transcriptomic and proteomic studies in sarcoidosis
Maneesh Bhargava, Shu-Yi Liao, Elliott D. Crouser, Lisa A. Maier, Sonia M. Leach
ERJ Open Research Jan 2022, 8 (1) 00621-2021; DOI: 10.1183/23120541.00621-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The landscape of transcriptomic and proteomic studies in sarcoidosis
Maneesh Bhargava, Shu-Yi Liao, Elliott D. Crouser, Lisa A. Maier, Sonia M. Leach
ERJ Open Research Jan 2022, 8 (1) 00621-2021; DOI: 10.1183/23120541.00621-2021
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Lung biology and experimental studies
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Broadening the scope for three dimensional (3D) printed airway stents
  • Tracheal complications of mechanical ventilation for COVID-19: a plot twist for survivors
  • Diffuse panniculitis in a teen male with ZZ alpha1-antitrypsin deficiency
Show more Research letter

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society